Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

403 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
Shimizu W, Kubota Y, Hoshika Y, Mozawa K, Tara S, Tokita Y, Yodogawa K, Iwasaki YK, Yamamoto T, Takano H, Tsukada Y, Asai K, Miyamoto M, Miyauchi Y, Kodani E, Ishikawa M, Maruyama M, Ogano M, Tanabe J; EMBODY trial investigators. Shimizu W, et al. Among authors: tanabe j. Cardiovasc Diabetol. 2020 Sep 25;19(1):148. doi: 10.1186/s12933-020-01127-z. Cardiovasc Diabetol. 2020. PMID: 32977831 Free PMC article. Clinical Trial.
Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale.
Kubota Y, Yamamoto T, Tara S, Tokita Y, Yodogawa K, Iwasaki Y, Takano H, Tsukada Y, Asai K, Miyamoto M, Miyauchi Y, Kodani E, Sato N, Tanabe J, Shimizu W. Kubota Y, et al. Among authors: tanabe j. Diabetes Ther. 2018 Oct;9(5):2107-2116. doi: 10.1007/s13300-018-0480-7. Epub 2018 Aug 10. Diabetes Ther. 2018. PMID: 30097993 Free PMC article.
Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus.
Mozawa K, Kubota Y, Hoshika Y, Tara S, Tokita Y, Yodogawa K, Iwasaki YK, Yamamoto T, Takano H, Tsukada Y, Asai K, Miyamoto M, Miyauchi Y, Kodani E, Maruyama M, Tanabe J, Shimizu W. Mozawa K, et al. Among authors: tanabe j. ESC Heart Fail. 2021 Oct;8(5):4161-4173. doi: 10.1002/ehf2.13509. Epub 2021 Jul 7. ESC Heart Fail. 2021. PMID: 34235875 Free PMC article. Clinical Trial.
Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus.
Hoshika Y, Kubota Y, Mozawa K, Tara S, Tokita Y, Yodogawa K, Iwasaki YK, Yamamoto T, Takano H, Tsukada Y, Asai K, Miyamoto M, Miyauchi Y, Kodani E, Maruyama M, Tanabe J, Shimizu W. Hoshika Y, et al. Among authors: tanabe j. Diabetes Ther. 2021 Aug;12(8):2241-2248. doi: 10.1007/s13300-021-01103-0. Epub 2021 Jul 8. Diabetes Ther. 2021. PMID: 34236577 Free PMC article.
Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial.
Hoshika Y, Kubota Y, Mozawa K, Tara S, Tokita Y, Yodogawa K, Iwasaki YK, Yamamoto T, Takano H, Tsukada Y, Asai K, Miyamoto M, Miyauchi Y, Kodani E, Maruyama M, Tanabe J, Shimizu W. Hoshika Y, et al. Among authors: tanabe j. J Card Fail. 2022 Jan;28(1):56-64. doi: 10.1016/j.cardfail.2021.07.022. Epub 2021 Aug 21. J Card Fail. 2022. PMID: 34425223 Free article. Clinical Trial.
Usefulness of rosuvastatin to prevent periprocedural myocardial injury in patients undergoing elective coronary intervention.
Takano H, Ohba T, Yamamoto E, Miyachi H, Inui K, Kawanaka H, Kamiya M, Kikuchi A, Takahashi Y, Tanabe J, Inami S, Takagi G, Asai K, Yasutake M, Ibuki C, Tanaka K, Kusama Y, Seino Y, Munakata K, Mizuno K; PRIMITIVE Study Investigators. Takano H, et al. Among authors: tanabe j. Am J Cardiol. 2013 Jun 15;111(12):1688-93. doi: 10.1016/j.amjcard.2013.02.018. Epub 2013 Mar 16. Am J Cardiol. 2013. PMID: 23507709 Clinical Trial.
403 results